|
|
Vol. 27.15 – 31 August, 2026
|
|
|
|
|
|
|
|
|
Scientists reported clinical and molecular data obtained during the nonrandomized Phase I part of the Phase I/II COMPARE trial, evaluating safety and efficacy of mivocabtagene autoleucel (miv-cel), an autologous fully human CD19 CAR T cell therapy, in rheumatoid arthritis. [Nature Medicine]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
|
|
|
Researchers developed defined culture conditions that enable long-term expansion of mouse and human granulocyte-monocyte progenitors (GMPs) while preserving progenitor identity and myeloid potential, establishing GMPs as a renewable engineering platform.
[Cell]
|
|
|
|
|
|
Investigators identified immunosenescence as a measurable and functionally consequential barrier to CAR T cell efficacy in chronic lymphocytic leukemia and a candidate for therapeutic modulation.
[Blood]
|
|
|
|
|
|
Scientists evaluated the intrinsic and extrinsic effects of deleting the negative regulator Regnase-1 in B7-H3-CAR T cells for the immunotherapy of osteosarcoma. [Cell Reports Medicine]
|
|
|
|
|
|
The authors identified tyrosine 218 (Y218) in the CD28 cytoplasmic domain as a critical regulatory site, and demonstrated that its phosphorylation is essential for optimal CAR-T cell activity.
[Molecular Therapy]
|
|
|
|
|
|
Researchers showed that CAR structure is a critical determinant of CD19 loss in tumor B cells. Specifically, repeated exposure to CD19–4-1BB-based CAR-T cells, but not CD19–CD28-based counterparts, drives FMC63-epitope and total CD19 protein loss. [Leukemia]
|
|
|
|
|
|
|
|
Successful macrophage immunotherapy requires solving two central in vivo determinants: preserving a therapeutically favorable functional state despite suppressive cues, and achieving robust, disease-selective localization and engagement. [Biotechnology Advances]
|
|
|
|
|
|
|
|
Dr. Trevor McGill at Oregon Health & Science University (OHSU) has received a major federal grant to develop a new generation of stem cell therapies that could one day help preserve sight for those with the disease without requiring long-term immune-suppressing drugs. [OHSU]
|
|
|
|
|
|
|
|
September 14-17, 2026 Columbus, Ohio, United States
|
|
|
|
|
|
|
|
|
|
|
University of British Columbia – Vancouver, British Columbia, Canada
|
|
|
|
|
|
|
University of Luxembourg – Luxembourg
|
|
|
|
|
|
|
MUSC College of Medicine – Charleston, South Carolina, United States
|
|
|
|
|
|
|
Yale School of Medicine – New Haven, Connecticut, United States
|
|
|
|
|
|
|
St. Jude Children’s Research Hospital – Memphis, Tennessee, United States
|
|
|
|
|
|